Department of Surgery, University of Sydney, Sydney, New South Wales, Australia.
Department of Cardiothoracic Surgery, Royal Adelaide Hospital, Adelaide, Australia.
ANZ J Surg. 2022 May;92(5):1007-1014. doi: 10.1111/ans.17667. Epub 2022 Apr 3.
The COVID-19 pandemic has had a significant impact on global surgery. In particular, deleterious effects of SARS-CoV-2 infection on the heart and cardiovascular system have been described. To inform surgical patients, we performed a systematic review and meta-analysis aiming to characterize outcomes of COVID-19 positive patients undergoing cardiac surgery.
The study protocol was registered with PROSPERO (CRD42021228533) and conformed with PRISMA 2020 and MOOSE guidelines. PubMed, Ovid MEDLINE and Web of Science were searched between 1 January 2019 to 24 February 2022 for studies reporting outcomes on COVID-19 positive patients undergoing cardiac surgery. Study screening, data extraction and risk of bias assessment were conducted in duplicate. Meta-analysis was conducted using a random-effects model where at least two studies had sufficient data for that variable.
Searches identified 4223 articles of which 18 studies were included with a total 44 patients undergoing cardiac surgery. Within these studies, 12 (66.7%) reported populations undergoing coronary artery bypass graft (CABG) surgery, three (16.7%) aortic valve replacements (AVR) and three (16.7%) aortic dissection repairs. Overall mean postoperative length of ICU stay was 3.39 (95% confidence interval (CI): 0.38, 6.39) and mean postoperative length of hospital stay was 17.88 (95% CI: 14.57, 21.19).
This systematic review and meta-analysis investigated studies of limited quality which characterized cardiac surgery in COVID-19 positive patients and demonstrates that these patients have poor outcomes. Further issues to be explored are effects of COVID-19 on decision-making in cardiac surgery, and effects of COVID-19 on the cardiovascular system at a cellular level.
COVID-19 大流行对全球外科产生了重大影响。特别是,已描述了 SARS-CoV-2 感染对心脏和心血管系统的有害影响。为了向外科患者提供信息,我们进行了系统评价和荟萃分析,旨在描述 COVID-19 阳性患者接受心脏手术的结果。
该研究方案已在 PROSPERO(CRD42021228533)上注册,并符合 PRISMA 2020 和 MOOSE 指南。在 2019 年 1 月 1 日至 2022 年 2 月 24 日期间,通过 PubMed、Ovid MEDLINE 和 Web of Science 搜索了报告 COVID-19 阳性患者接受心脏手术结果的研究。研究筛选、数据提取和偏倚风险评估均由两人进行。至少有两项研究具有该变量的足够数据时,使用随机效应模型进行荟萃分析。
搜索共确定了 4223 篇文章,其中纳入了 18 项研究,共 44 名患者接受了心脏手术。在这些研究中,12 项(66.7%)报告了接受冠状动脉旁路移植术(CABG)的人群,3 项(16.7%)报告了主动脉瓣置换术(AVR),3 项(16.7%)报告了主动脉夹层修复术。总体而言,术后 ICU 住院时间的平均值为 3.39(95%置信区间:0.38,6.39),术后住院时间的平均值为 17.88(95%置信区间:14.57,21.19)。
本系统评价和荟萃分析调查了质量有限的研究,这些研究描述了 COVID-19 阳性患者的心脏手术情况,表明这些患者的预后较差。需要进一步探讨的问题是 COVID-19 对心脏手术决策的影响,以及 COVID-19 对心血管系统的细胞水平的影响。